Philip Gutry - Graphite Bio Chief Officer
| GRPHDelisted Stock | USD 2.67 0.05 1.84% |
Insider
Philip Gutry is Chief Officer of Graphite Bio
| Age | 51 |
| Phone | 650 484 0886 |
| Web | https://graphitebio.com |
Graphite Bio Management Efficiency
The company has return on total asset (ROA) of (0.1799) % which means that it has lost $0.1799 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5195) %, meaning that it created substantial loss on money invested by shareholders. Graphite Bio's management efficiency ratios could be used to measure how well Graphite Bio manages its routine affairs as well as how well it operates its assets and liabilities.Graphite Bio currently holds 362 K in liabilities with Debt to Equity (D/E) ratio of 0.02, which may suggest the company is not taking enough advantage from borrowing. Graphite Bio has a current ratio of 26.53, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Graphite Bio's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Robert Coutts | Achilles Therapeutics PLC | 40 | |
| Stacy Markel | Nuvation Bio | 59 | |
| Michele Anderson | Assembly Biosciences | N/A | |
| Sergey Yurasov | Nuvation Bio | 51 | |
| Bronson Crouch | Instil Bio | 51 | |
| Erin Colgan | Sensei Biotherapeutics | 43 | |
| Karl MD | Achilles Therapeutics PLC | 57 | |
| Jamie Moore | CytomX Therapeutics | N/A | |
| MD FACP | NextCure | 71 | |
| Adam Zlotnick | Assembly Biosciences | N/A | |
| Solomon Langermann | NextCure | 64 | |
| Sumita JD | Instil Bio | 50 | |
| Sergio Quezada | Achilles Therapeutics PLC | 49 | |
| Tharaknath Rao | Assembly Biosciences | N/A | |
| MBA BS | CytomX Therapeutics | 45 | |
| W Vernon | Nuvation Bio | 65 | |
| Steven Fuller | Sensei Biotherapeutics | N/A | |
| Gary Hattersley | Nuvation Bio | 57 | |
| Mark Dudley | Instil Bio | N/A | |
| Thomas Templeman | Nuvation Bio | 60 | |
| Timothy Mayer | NextCure | 59 | |
Management Performance
| Return On Equity | -0.52 | |||
| Return On Asset | -0.18 |
Graphite Bio Leadership Team
Elected by the shareholders, the Graphite Bio's board of directors comprises two types of representatives: Graphite Bio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Graphite. The board's role is to monitor Graphite Bio's management team and ensure that shareholders' interests are well served. Graphite Bio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Graphite Bio's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Stephanie Yao, Vice Relations | ||
| Maria MD, Academic Board | ||
| Christine PMP, Chief Operations | ||
| Jerry Cacia, Chief Officer | ||
| Philip Gutry, Chief Officer | ||
| Jane Grogan, Chief Officer | ||
| MD FACC, CEO Pres | ||
| Daniel Dever, CoFounder Research | ||
| Alethia Young, Chief Officer | ||
| Kimberlee CPA, CEO and Presidentident | ||
| Matthew MD, Academic Director |
Graphite Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Graphite Bio a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.52 | |||
| Return On Asset | -0.18 | |||
| Current Valuation | 1.88 M | |||
| Shares Outstanding | 58.24 M | |||
| Shares Owned By Insiders | 9.17 % | |||
| Shares Owned By Institutions | 84.40 % | |||
| Number Of Shares Shorted | 704.04 K | |||
| Price To Earning | 0.70 X | |||
| Price To Book | 1.01 X | |||
| EBITDA | (70.7 M) |
Currently Active Assets on Macroaxis
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Other Consideration for investing in Graphite Stock
If you are still planning to invest in Graphite Bio check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Graphite Bio's history and understand the potential risks before investing.
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |